Why Millions from California Won't Get VCs to Fund Stem Cell Start-Ups--But What Will
This article was originally published in Start Up
Executive Summary
Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.
You may also be interested in...
Kleiner Perkins Prepares for Biotech's New Golden Age
Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.
Kleiner Perkins Prepares for Biotech's New Golden Age
Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.
Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets
In 2003, the combined US potential market for tissue-engineering products totaled approximately $58.1 billion. By 2013, the potential market is expected to increase at a compound rate of 4.8%, reaching $92.8 billion, with a number of segments growing at an even faster rate than the market overall.